Bevirimat: A New HIV-1 Maturation Inhibitor
Author Information
Author(s): Cheryl A. Stoddart, Pheroze Joshi, Barbara Sloan, Jennifer C. Bare, Philip C. Smith, Graham P. Allaway, Carl T. Wild, David E. Martin
Primary Institution: Gladstone Institute of Virology and Immunology, University of California at San Francisco
Hypothesis
Can bevirimat effectively reduce HIV-1 viral load and protect T cells in an animal model?
Conclusion
Bevirimat significantly reduces HIV-1 viral load and protects T cells in SCID-hu Thy/Liv mice.
Supporting Evidence
- Bevirimat reduced viral RNA by more than 2 log10.
- Treatment preserved immature and mature T-cell populations.
- Bevirimat was effective against both wild-type and drug-resistant HIV-1.
Takeaway
Bevirimat is a new medicine that helps fight HIV by stopping the virus from maturing, which keeps the immune system stronger.
Methodology
Oral administration of bevirimat to HIV-1-infected SCID-hu Thy/Liv mice was used to assess its antiviral activity.
Limitations
The study was conducted in a mouse model, which may not fully replicate human responses.
Participant Demographics
SCID-hu Thy/Liv mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website